Skip to main content Back to Top
Advertisement

3/8/2020

Cefuroxime Sodium Injection

Products Affected - Description

    • Zinacef powder for solution for injection, Teligent, 1.5 gram, vial, 10 count, NDC 24987-0354-10 - discontinued
    • Zinacef powder for solution for injection, Teligent, 750 mg, vial, 10 count, NDC 24987-0352-10 - discontinued

Reason for the Shortage

    • Sagent had cefuroxime injection on shortage due to manufacturing delays and increased demand.
    • Teligent discontinued all Zinacef presentations in February 2018.
    • Hikma did not provide a reason for the cefuroxime injection shortage. They are not currently marketing the 7.5 gram vials.

Available Products

    • Cefuroxime powder for solution for injection, Hikma, 1.5 gram, vial, 25 count, NDC 00143-9977-22
    • Cefuroxime powder for solution for injection, Hikma, 750 mg, vial, 25 count, NDC 00143-9979-22
    • Cefuroxime powder for solution for injection, Sagent, 1.5 gram, vial, 25 count, NDC 25021-0119-20
    • Cefuroxime powder for solution for injection, Sagent, 750 mg, vial, 25 count, NDC 25021-0118-10

Estimated Resupply Dates

    • Teligent is estimating a relaunch of Zinacef 750 mg vials and 1.5 gram vials in early-2020

Updated

Updated March 8, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created January 25, 2013 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.